Capsid inhibitors disrupt the HIV capsid, a protective protein shell for HIV's genetic material and replication enzymes.

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). Gilead presented data on two novel ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating ...

A few days later, confidence in the drug was dented again when Gilead Sciences called a halt to a mid-stage trial of islatravir given alongside its HIV capsid inhibitor lenacapavir, which is ...

The impact of long-acting injectables (LAIs) for HIV was discussed at the 35th ESCMID Global conference in Vienna, Austria.

They began by studying how HIV is built on a molecular level. They discovered that the capsid's structure is extremely sensitive, making it an ideal target for disrupting the virus' ability to ...

At the time, most existing HIV drugs worked by interfering with the ... But Tomas envisioned a different solution - one that disrupted the viral capsid, the cone-shaped protein structure that ...

People who participated in the study also had HIV-1 RNA levels of at least 3000 copies/mL. The trial of VH499, an investigational capsid inhibitor, showed that all oral doses (25mg, 100mg ...